Corbus Pharmaceuticals Holdings Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Corbus Pharmaceuticals Holdings, Inc. (CRBP) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-40.21-44.60-42.35-45.64-111.27-71.45-55.67
Depreciation & Amortization0.590.640.763.041.691.230.49
Stock Based Compensation6.153.475.729.7312.460.000.00
Change in Working Capital-5.584.09-3.30-14.71-3.206.5017.01
Change in Accounts Receivable0.000.000.001.621.060.000.00
Change in Accounts Payable1.601.03-0.26-5.96-3.470.000.00
Change in Other Working Capital0.593.07-3.04-11.36-0.800.000.00
Other Operating Activities0.59-0.020.559.090.3418.000.42
Net Cash from Operating Activities-41.79-36.10-37.54-48.18-99.69-45.72-30.07
Investing Activities
Capital Expenditures0.000.00-0.010.05-0.482.74-2.30
Purchases of Investments-180.8035.6430.08-73.390.000.000.00
Sales/Maturities of Investments59.49-33.8930.08-73.390.000.000.00
Net Cash from Investing Activities-121.3135.6430.07-73.42-0.48-2.74-2.30
Financing Activities
Debt Repayment-15.48-3.25-2.37-0.93-0.95-0.61-0.43
Common Stock Issued182.060.050.0062.59142.2040.6812.05
Other Financing Activities0.00-0.190.00-1.82-6.04-2.57-0.69
Net Cash from Financing Activities166.58-2.82-0.5360.82154.8738.4611.42
Summary
Net Change in Cash3.47-3.28-8.00-60.7854.70-10.00-20.95
Cash at Beginning of Period14.3917.6725.6886.4531.7541.7562.70
Cash at End of Period17.87-69.9917.6725.6886.4531.7541.75
Free Cash Flow-41.79-36.10-37.56-48.21-100.17-48.46-32.37
Supplemental Disclosures
Interest Paid2.822.611.971.740.630.030.01